Defeating the trypanosomatid trio: proteomics of the protozoan parasites causing neglected tropical diseases

Parthasarathy, Anutthaman; Kalesh, Karunakaran A.

doi:10.1039/d0md00122h

Cited by 22 publications

(13 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both observations represent a validation of biological relevance for the transcriptome and translatome data sets, as genes related to the infective stages are transcribed but are not selected for translation in the epimastigote stage. Finally, 4,524 protein groups were detected at the proteomic level, which corresponds to 4,918 genes, i.e., 47%, representing a high coverage of the genome in comparison to previous studies ( 48 , 49 ) ( Fig. 3A ).…”

Section: Resultsmentioning

confidence: 59%

Extensive Translational Regulation through the Proliferative Transition of Trypanosoma cruzi Revealed by Multi-Omics

Chávez

Urbaniak

Benz

et al. 2021

mSphere

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 59%

Extensive Translational Regulation through the Proliferative Transition of Trypanosoma cruzi Revealed by Multi-Omics

Chávez

Urbaniak

Benz

et al. 2021

mSphere

View full text Add to dashboard Cite

show abstract

“…Currently, several tools are being used in the development of vaccines in the context of trypanosomatids, such as immunoinformatic, genomic, and proteomic techniques that mainly contribute to the identification of new antigenic targets and epitopes of these parasites [ 31 , 32 ], as well as in the development of various immunization protocols in experimental models [ 33 , 34 , 35 , 36 , 37 , 38 ]. Several proteins and virulence factors are biologically and structurally shared among protozoa of the trypanosomatid family and therefore could be used as possible targets for the development of vaccines, such as surface glycoproteins [ 39 , 40 , 41 ], cysteine proteases [ 42 , 43 ], and metalloproteases [ 44 , 45 , 46 ].…”

Section: Vaccines To Control Diseases Caused By Trypanosomatids: Wmentioning

confidence: 99%

VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

et al. 2021

View full text Add to dashboard Cite

Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.

show abstract

“…In kinetoplastids, proteomics have been used to understand the differentiation processes in the various life cycle stages, to identify biomarkers, to support vaccine development, as well as to elucidate the MoA/MoR of drugs ( Table 4 ) [ 85 , 138 , 139 , 140 , 141 ]. Several techniques can be used to compare the relative protein expression, but most employ labelling techniques such as 2D differential gel electrophoresis (2D-DIGE), stable isotope labeling of amino acids in cell culture (SILAC), or isobaric tags for relative and absolute quantitation (iTRAQ) [ 18 , 142 ].…”

Section: Proteomicsmentioning

confidence: 99%

Experimental Strategies to Explore Drug Action and Resistance in Kinetoplastid Parasites

et al. 2020

View full text Add to dashboard Cite

Kinetoplastids are the causative agents of leishmaniasis, human African trypanosomiasis, and American trypanosomiasis. They are responsible for high mortality and morbidity in (sub)tropical regions. Adequate treatment options are limited and have several drawbacks, such as toxicity, need for parenteral administration, and occurrence of treatment failure and drug resistance. Therefore, there is an urgency for the development of new drugs. Phenotypic screening already allowed the identification of promising new chemical entities with anti-kinetoplastid activity potential, but knowledge on their mode-of-action (MoA) is lacking due to the generally applied whole-cell based approach. However, identification of the drug target is essential to steer further drug discovery and development. Multiple complementary techniques have indeed been used for MoA elucidation. In this review, the different ‘omics’ approaches employed to define the MoA or mode-of-resistance of current reference drugs and some new anti-kinetoplastid compounds are discussed.

show abstract

Defeating the trypanosomatid trio: proteomics of the protozoan parasites causing neglected tropical diseases

Abstract: This review highlights the key roles of proteomic techniques in the study of Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei parasites.

Cited by 22 publications

References 195 publications

Extensive Translational Regulation through the Proliferative Transition of Trypanosoma cruzi Revealed by Multi-Omics

Extensive Translational Regulation through the Proliferative Transition of Trypanosoma cruzi Revealed by Multi-Omics

VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases

Experimental Strategies to Explore Drug Action and Resistance in Kinetoplastid Parasites

Contact Info

Product

Resources

About